Alerta

HUMANIZED ANTI-CD45 ANTIBODIES AND USES THEREOF

Resumen de: US2025326856A1

Novel chimeric and/or humanized forms of the anti-CD45 BC8 antibody are described. The disclosed chimeric or humanized antibodies can be used as research, diagnostic, or therapeutic tools against CD45-related disorders, such as hematologic malignancies including acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL), other myeloid and lymphoid disorders, other cancers, as well as non-malignant disorders, such as autoimmune disorders, infections, inherited blood disorders, and metabolic disorders.

REAGENTS AND METHODS FOR DETECTING OR MODULATING CBL AND/OR CBL-B IN PATIENTS

Resumen de: WO2025217743A1

Systemic lupus erythematosus (SLE) is an autoimmune disease with multisystem involvement and is associated with significant morbidity and mortality. The diagnosis of SLE is challenging because signs and symptoms vary considerably from person to person, may change over time, and may overlap with those of many other disorders. There is thus a need for better tools and assays for the diagnosis and assessment of SLE. The present application discloses novel methods for the diagnosis and follow-up of SLE based on the detection of the levels of Casitas B-lineage lymphoma (CBL) and/or CBL-B in T lymphocytes from a subject, as well as novel methods for treating a subject suffering from SLE or preventing the development of SLE in an at-risk subject through the administration of an agent that increases the expression or activity of CBL and/or CBL-B in T lymphocytes from the subject, and/or the depletion of ICOS+ T cells.

HETERO (AROMATIC) RING-SUBSTITUTED CYCLIC DIAMINE COMPOUND AND USE THEREOF IN PREPARATION OF DRUG FOR TREATING AND/OR PREVENTING TUMORS

Resumen de: WO2025218293A1

The present invention relates to a hetero (aromatic) ring-substituted cyclic diamine compound, the preparation thereof and the use thereof in the preparation of a drug for treating and/or preventing tumors. The structural formula of the compound is as shown in (I). The compound has a significant inhibitory effect on the growth of cells of tumors such as leukemia, lymphoma, breast cancer, melanoma, ovarian cancer, colorectal cancer, cervical cancer, lung cancer, prostate cancer, esophageal cancer, glioma, kidney cancer, nasopharyngeal carcinoma, liver cancer, gastric cancer and pancreatic cancer. Compared with the prior art, the compound of the present invention has a broad-spectrum anti-tumor activity, has a good effect on inhibiting tumors, and has an effect of degrading PD-L1 proteins, and is thus a PD-L1 immunomodulator.

ALK POLYPEPTIDES AND METHODS OF USE THEREOF

Resumen de: US2025325644A1

The invention features immunogenic compositions containing anaplastic lymphoma kinase (ALK) polypeptides and methods of use thereof. The immunogenic compositions and methods of the invention may be used to treat a disease associated with ALK in a subject, such as cancer (e.g., a solid tumor cancer or an ALK+ cancer).

ANTI-CLL1 SINGLE-DOMAIN ANTIBODY AND USE THEREOF

Resumen de: EP4635981A1

The present invention relates to an anti-CLL1 single-domain antibody and use thereof, specifically, to a single-domain antibody having an amino acid sequence of SEQ ID No. 1. The single-domain antibody has high affinity and can specifically target CLL1-positive cells, and can be applied to the detection of CLL1 expression in bone marrow cells of acute myeloid leukemia (AML) patients. The single-domain antibody can be prepared into a specific antibody drug clinically used for preventing and treating CLL1 target-related diseases (such as acute myeloid leukemia, myelodysplastic syndromes, or chronic myeloid leukemia), and can also be used in the preparation of CLL1-targeting chimeric antigen receptor (CAR) cells or diagnostic kits for CLL1 protein detection and the like. The single-domain antibody drug has a stable structure, small molecular size, ease of recombinant expression, and low production cost. It can be used alone or employed as a drug delivery system to carry related drugs, which has broad prospects and important significance in the fields of pharmaceutical application, clinical diagnosis, and related fields.

METHODS OF TREATING MYELODYSPLASTIC SYNDROME

Nº publicación: KR20250151565A 21/10/2025

Solicitante:

제론코포레이션

Resumen de: ZA202000070B

This disclosure provides methods of treating a myelodysplastic syndrome (MDS) in a subject that is naive to treatment with an agent selected from a hypomethylating agent (HMA) and lenalidomide, or both. The method includes administering to the subject an effective amount of a telomerase inhibitor, such as e.g. imetelstat or imetelstat sodium. In some cases, the subject treated is classified as low or intermediate-1 IPSS risk MDS and/or have MDS relapsed/refractory to Erythropoiesis-Stimulating Agent (ESA).